Analysis on the therapeutic effect of Cangfu Daotan Decoction combined with drospirenone and ethinylestradiol tablets (II) on patients with polycystic ovary syndrome

IF 2.5 3区生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY

Prostaglandins & other lipid mediators Pub Date : 2023-11-18 DOI:10.1016/j.prostaglandins.2023.106801

Yanhong Fu , Pengpeng Xie , Qingping Yang , Peng Chen , Jingwei Yu

{"title":"Analysis on the therapeutic effect of Cangfu Daotan Decoction combined with drospirenone and ethinylestradiol tablets (II) on patients with polycystic ovary syndrome","authors":"Yanhong Fu , Pengpeng Xie , Qingping Yang , Peng Chen , Jingwei Yu","doi":"10.1016/j.prostaglandins.2023.106801","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>This study was designed to investigate the therapeutic effect of Cangfu Daotan Decoction (CDD) combined with drospirenone and ethinylestradiol tablets (II) on patients with polycystic ovary syndrome (PCOS).</p></div><div><h3>Methods</h3><p>Patients with PCOS were gathered from September 2020 to September 2022 and divided into the experimental group (n = 36), treated with CDD combined with drospirenone and ethinylestradiol tablets (II), and the control group (n = 41), received only drospirenone and ethinylestradiol tablets (II). Levels of sex hormone, obesity, blood glucose, blood lipid were detected and compared between the two groups pre- and post-treatment. The treatment efficacy, Traditional Chinese Medicine (TCM) syndrome score, adverse drug reactions, and pregnancy rate were compared as well.</p></div><div><h3>Results</h3><p>After treatment, the experimental group had a higher treatment efficacy (94.44% vs 73.17%, <em>P</em> < 0.05) and a higher pregnancy rate (44.44% vs 21.95%, <em>P</em> < 0.05) than the control group, but the difference in the incidence of adverse drug reactions was not statistically significant (<em>P</em><span> > 0.05). Compared with control group, TCM syndrome score and levels of fasting blood glucose, fasting insulin, homeostasis model assessment of insulin resistance (HOMA-IR), and waist circumference of the experimental group after treatment displayed remarkable reduction (</span><em>P</em> < 0.05), while the levels of estradiol (E2) and high-density lipoprotein cholesterol (HDL-C) showed a remarkable increase (<em>P</em> < 0.05).</p></div><div><h3>Conclusion</h3><p>CDD in combination with drospirenone and ethinylestradiol tablets (II) may be effective in treating PCOS by improving obesity, glucose metabolism and lipid metabolism with no serious adverse events, making it a feasible clinical practice option.</p></div>","PeriodicalId":21161,"journal":{"name":"Prostaglandins & other lipid mediators","volume":"170 ","pages":"Article 106801"},"PeriodicalIF":2.5000,"publicationDate":"2023-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Prostaglandins & other lipid mediators","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1098882323000989","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

This study was designed to investigate the therapeutic effect of Cangfu Daotan Decoction (CDD) combined with drospirenone and ethinylestradiol tablets (II) on patients with polycystic ovary syndrome (PCOS).

Methods

Patients with PCOS were gathered from September 2020 to September 2022 and divided into the experimental group (n = 36), treated with CDD combined with drospirenone and ethinylestradiol tablets (II), and the control group (n = 41), received only drospirenone and ethinylestradiol tablets (II). Levels of sex hormone, obesity, blood glucose, blood lipid were detected and compared between the two groups pre- and post-treatment. The treatment efficacy, Traditional Chinese Medicine (TCM) syndrome score, adverse drug reactions, and pregnancy rate were compared as well.

Results

After treatment, the experimental group had a higher treatment efficacy (94.44% vs 73.17%, P < 0.05) and a higher pregnancy rate (44.44% vs 21.95%, P < 0.05) than the control group, but the difference in the incidence of adverse drug reactions was not statistically significant (P > 0.05). Compared with control group, TCM syndrome score and levels of fasting blood glucose, fasting insulin, homeostasis model assessment of insulin resistance (HOMA-IR), and waist circumference of the experimental group after treatment displayed remarkable reduction (P < 0.05), while the levels of estradiol (E2) and high-density lipoprotein cholesterol (HDL-C) showed a remarkable increase (P < 0.05).

Conclusion

CDD in combination with drospirenone and ethinylestradiol tablets (II) may be effective in treating PCOS by improving obesity, glucose metabolism and lipid metabolism with no serious adverse events, making it a feasible clinical practice option.

Abstract Image

查看原文本刊更多论文

苍妇导痰汤联合屈螺酮炔雌醇片治疗多囊卵巢综合征的疗效分析。

目的:观察苍复导痰汤联合屈螺酮炔雌醇片治疗多囊卵巢综合征(PCOS)的疗效。方法:收集2020年9月~ 2022年9月PCOS患者，分为实验组(n=36)和对照组(n=41)，实验组采用CDD联合降螺酮和炔雌醇片(II)治疗，对照组仅采用降螺酮和炔雌醇片(II)治疗，检测两组治疗前后性激素、肥胖、血糖、血脂水平，并进行比较。比较两组患者的治疗效果、中医证候评分、药物不良反应及妊娠率。结果:治疗后，试验组治疗有效率更高(94.44% vs 73.17%， P0.05)。与对照组比较，试验组治疗后中医证候评分及空腹血糖、空腹胰岛素、胰岛素抵抗稳态模型评估(HOMA-IR)水平、腰围均显著降低(p)。CDD联合降螺酮炔雌醇片(II)可通过改善肥胖、糖代谢和脂质代谢而有效治疗PCOS，且无严重不良事件，是一种可行的临床实践选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Prostaglandins & other lipid mediators 生物-生化与分子生物学

CiteScore

5.80

自引率

3.40%

发文量

审稿时长

2 months

期刊介绍： Prostaglandins & Other Lipid Mediators is the original and foremost journal dealing with prostaglandins and related lipid mediator substances. It includes basic and clinical studies related to the pharmacology, physiology, pathology and biochemistry of lipid mediators. Prostaglandins & Other Lipid Mediators invites reports of original research, mini-reviews, reviews, and methods articles in the basic and clinical aspects of all areas of lipid mediator research: cell biology, developmental biology, genetics, molecular biology, chemistry, biochemistry, physiology, pharmacology, endocrinology, biology, the medical sciences, and epidemiology. Prostaglandins & Other Lipid Mediators also accepts proposals for special issue topics. The Editors will make every effort to advise authors of the decision on the submitted manuscript within 3-4 weeks of receipt.